Home Title

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

COVID 19

Following updated Government and Health Authority advice, to reduce the spread of COVID 19 and to reduce any risks to our employees, all employees across the Group are working from home, aside from those critical to the continued manufacture of our products. As part of our commitment to putting patients first, we are continually monitoring our supply chain and manufacturing capabilities and are confident that we will continue to be able to supply our allergy therapies and diagnostics. We continue to monitor the situation and are committed to maintain our mission of transforming allergy treatment.

+7% Revenue growth at constant (and 6% at reported rate)
25% Increase in pre-R&D operating profit to £14.2m (2019: £11.3m)
£37.0m Strong cash balance at 30 June 2020 (2019: £27.4m)
£7.1m Net profit for the year including one-off legal settlement of £3.2m (2019: £3.5m)

Our year in numbers

2020 was another year of growth, with a record level of pre R&D operating profit (25%) supported by robust sales and operational efficiencies.

Annual Report 2020

Take your career to new heights

Our culture and values